Literature DB >> 3643705

Processing of apolipoprotein B-100 of human plasma low density lipoproteins by tissue and plasma kallikreins.

A D Cardin, R L Jackson, V H Donaldson, J Chao, H S Margolius.   

Abstract

Human plasma low density lipoproteins (LDL) are the major carriers of cholesterol and cholesteryl esters in the circulation. Their increased levels correlate positively with increased risk of coronary artery disease. LDL contain a single major apolipoprotein of apparent molecular weight (Mr) = 550,000, designated apolipoprotein B-100 (apoB-100), and in some LDL preparations, minor components termed apoB-74 (410,000) and apoB-26 (145,000). The structural relationship of the apoB-74 and -26 proteins to the apoB-100 has remained obscure and their roles in cholesterol metabolism are unknown. In the present study, we show that the addition of kaolin to plasma anticoagulated with EDTA induces the proteolytic cleavage of apoB-100. As a result, two apoB peptides are produced with Mr indistinguishable from plasma apoB-74 and -26. The specific cleavage of apoB-100 was mimicked in vitro by purified human plasma and tissue kallikreins. In contrast, thrombin, factor Xa, plasmin, trypsin, and chymotrypsin did not produce these peptides when incubated with LDL. The findings of the study suggest that apoB-74 and -26 are proteolytic fragments of apoB-100 and that the endogenous protease has a kallikrein-like specificity for DLD-apoB-100. The role of plasma and tissue kallikreins in cholesterol metabolism remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3643705     DOI: 10.1007/978-1-4684-5143-6_27

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  1 in total

1.  Kinetic study of neuropeptide Y (NPY) proteolysis in blood and identification of NPY3-35: a new peptide generated by plasma kallikrein.

Authors:  Karim Abid; Bertrand Rochat; Paul-Gerhard Lassahn; Reto Stöcklin; Sophie Michalet; Noureddine Brakch; Jean-Francois Aubert; Bilgin Vatansever; Patricia Tella; Ingrid De Meester; Eric Grouzmann
Journal:  J Biol Chem       Date:  2009-07-20       Impact factor: 5.157

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.